GlassScriptPhysician profile
Letrice Mason
NPI 1881140705
$6,114.30
in general payments reported to CMS, 2019-2025
15 companies · $55.07 in 2025
The $55.07 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $1,253 · 2023: $4,418 · 2024: $65.21 · 2025: $55.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $439 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $438.71 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $4,193.72 | 2022-2025 | Slynd, Nuvessa, Nuvessa |
| Pfizer INC. | $1,108.61 | 2022-2023 | |
| Astellas Pharma US INC | $224.57 | 2023 | Veozah |
| Mayne Pharma Commercial LLC | $124.86 | 2021-2022 | |
| Evofem Biosciences, INC. | $124.09 | 2021-2024 | |
| Organon LLC | $61.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.66 | 2023 | |
| Boston Scientific Corporation | $53.62 | 2021 | |
| Myovant Sciences INC. | $46.82 | 2021 | |
| Abbvie INC. | $28.16 | 2024 | |
| Mylan Pharmaceuticals INC. | $25.46 | 2022 | |
| Myriad Women'S Health, INC. | $19.35 | 2023 | Myrisk |
| Currax Pharmaceuticals LLC | $15.25 | 2021 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Avion Pharmaceuticals | $14.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Letrice Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.